A Multicenter Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

• Register: EUCTR
• Last refreshed on: 16 February 2015
• Main ID: EUCTR2010-018431-18-DE
• Date of registration: 24/06/2010
• Prospective Registration: Yes
• Primary sponsor: Janssen Biologics B.V.
• Public title: A Multicenter Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
• Scientific title: Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE® (infliximab) and Placebo in the Prevention of Recurrence in Crohn’s Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence - PREVENT
• Date of first enrolment: 23/08/2010
• Target sample size: 290
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-018431-18
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2

Countries of recruitment

Australia, Austria, Belgium, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, United Kingdom

Contacts

• Name: Clinical Registry Group
• Affiliation: Janssen-Cilag International NV

• Name: Clinical Registry Group
• Affiliation: Janssen-Cilag International NV

Key inclusion & exclusion criteria

Inclusion criteria:
Have a documented diagnosis of CD confirmed by endoscopic, histologic and/or radiologic studies prior to resection or by tissue obtained at resection; Have undergone an ileocolonic surgical resection; Patients must also be at an increased risk of recurrence of active CD; Patients must not have previously discontinued infliximab as a result of tolerability issues or they must be naive to treatment with infliximab. Provided patients meet the above criteria pertaining to infliximab, they are eligible to enroll if they received prior treatment with adalimumab and/or certolizumab. Patients must undergo screening for HBV; Baseline CDAI < 200; Have adequate blood and liver test values.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 290
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Have a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening; Have a chest radiograph within 3 months prior to the first infusion of study agent that shows a clinically significant abnormality, such as a malignancy or infection, or any abnormalities suggestive of TB; Have macroscopically active CD which was not resected at the time of surgery; Do not meet the criteria for being at an increased risk of postoperative recurrence of active CD as outlined in the inclusion criteria; Have evidence of an active infection at the time of randomization or have had a serious infection not related to CD (e.g., hepatitis, pneumonia, or pyelonephritis), within 6 months prior to screening; Have or have had an opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening; Have any known malignancy or history of malignancy within the 5-year period prior to screening (with the exception of squamous or basal cell carcinoma of the skin that has been completely excised without evidence of recurrence); Have any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Crohn’s disease (CD)
MedDRA version: 16.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders

Intervention(s)

Trade Name: Remicade
Product Name: REMICADE
Pharmaceutical Form: Powder for concentrate for solution for infusion
INN or Proposed INN: INFLIXIMAB
CAS Number: 170277-31-3
Current Sponsor code: INFLIXIMAB
Other descriptive name: n/a
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Powder for concentrate for solution for infusion
Route of administration of the placebo: Intravenous use

Primary Outcome(s)

Primary end point(s): The primary endpoint is clinical recurrence of CD prior to or at Week 76.
Clinical recurrence is a composite endpoint defined by the following:
• A = 70-point increase from baseline in CDAI score; and
• A CDAI score of = 200; and
• Evidence of endoscopic recurrence. Endoscopic recurrence is defined
as a Rutgeerts score of = i2 at the anastomotic site or its equivalent
elsewhere in the GI tract; and
• If in the opinion of the investigator, the patient's symptoms are
predominantly diarrheal, a negative stool test for C. difficile must be
present to confirm the true CD nature of the flare.
or
• Developing a new draining external fistula.
or
• Re-opening and draining of a previously existing external fistula.
or
• Developing a new internal fistula.
or
• Developing a new perianal abscess.
or
• Developing a new intra-abdominal abscess more than 3 months after
the date of the index surgery.
Note that "baseline" CDAI refers to the CDAI collected during the
screening period that qualified the patient for the study.
Patients who meet the criteria for clinical recurrence at Week 76 or at
any time point prior to Week 76 will be considered to have clinical
recurrence through Week 76.
Patients who initiate a prohibited CD-related medication or have a
prohibited use of a CD medication prior to Week 76 will be considered to
have had clinical recurrence.
Patients who have surgery for CD prior to Week 76 will be considered to
have had clinical recurrence.

Secondary Objective: The major secondary objective will be to compare the efficacy of infliximab with that of placebo in the prevention of endoscopic recurrence of CD through Week 76, defined as a Rutgeerts score = i2 either at the anastomosis or elsewhere in the gastrointestinal [GI] tract, in patients who are at an increased risk of active CD recurrence following ileocolonic resection.

Timepoint(s) of evaluation of this end point: Week 76

Main Objective: The primary objective of this study will be to compare the efficacy of infliximab with that of placebo in the prevention of clinical recurrence of CD through Week 76, defined as a composite endpoint that requires endoscopic confirmation of recurrence, in patients who are at an increased risk of active CD recurrence following ileocolonic resection.

Secondary Outcome(s)

Secondary end point(s): Compare the efficacy of infliximab with that of placebo in the prevention of endoscopic recurrence of CD : Presence or absence of mucosal inflammation and ulceration will be evaluated via video ileocolonoscopy at Week 76, and to ensure that there is no recurrence of Crohn's Disease in the colon

Timepoint(s) of evaluation of this end point: Week 76

Secondary ID(s)

REMICADECRD3001

Source(s) of Monetary Support

Janssen Biotech Inc.